Document Detail

Potential economic impact of increasing low dose aspirin usage on CVD in the US.
MedLine Citation:
PMID:  20738228     Owner:  NLM     Status:  In-Process    
BACKGROUND: Cardiovascular disease (CVD) is a leading cause of death in the US and Western Europe, but regular use of preventive low-dose aspirin has proven effective in preventing CVD events. The purpose of this study was to explore the potential economic impact in the US if preventive aspirin usage were to be increased in line with clinical guidelines for primary and secondary prevention.
METHODS: The risk profile of the US population was characterized using NHANES data, and Framingham cardiovascular risk equations were applied to calculate risk for myocardial infarction, angina and ischemic stroke according to age and gender. Primary and secondary patients were considered separately. Using publicly available unit costs, a budget impact model calculated the annual impact of increased preventive aspirin usage considering gastrointestinal bleeding and hemorrhagic stroke adverse events and diminishing aspirin adherence over a 10-year time horizon.
RESULTS: In a base population of 1,000,000 patients, full implementation of clinical guidelines would potentially prevent an additional 1273 myocardial infarctions, 2184 angina episodes and 565 ischemic strokes in primary prevention patients and an additional 578 myocardial infarctions, and 607 ischemic strokes in secondary prevention patients. This represents a total savings of $79.6 million for primary prevention and $32.2 million for secondary and additional out-of-pocket expense to patients of $29.0 million for primary prevention and $2.6 million for secondary prevention for the cost of aspirin.
CONCLUSIONS: This budgetary model suggests that there is a strong economic case, both for payers and society, to encourage aspirin use for patients at appropriate risk and per clinical guidelines. It also provides an example of how minimizing costs do not necessarily have to imply a rationing of care. Limitations include the exclusion of other CVD interventions in the analysis.
Stephanie C Manson; Agnes Benedict; Feng Pan; Kim U Wittrup-Jensen; A Mark Fendrick
Related Documents :
14522478 - Triple antiplatelet therapy during percutaneous coronary intervention is associated wit...
18020598 - Lepirudin: a review of its potential place in the management of thrombotic disorders.
15259448 - Coagulation, inflammation and myocardial dysfunction in unstable coronary artery diseas...
11246058 - Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on le...
19293668 - Increased circulating placental growth factor during percutaneous coronary intervention...
10654508 - Perfusion-assisted direct coronary artery bypass: selective graft perfusion in off-pump...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current medical research and opinion     Volume:  26     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  2365-73     Citation Subset:  IM    
United BioSource Corporation, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
Next Document:  The importance of being earnest about shank and thigh kinematics especially when using ankle-foot or...